Preclinical study demonstrates improved glycaemic control and increased beta-cell mass in db/db mice treated with ZP3022, suggesting therapeutic potential for diabetes.
The novel GLP-1-gastrin dual agonist, ZP3022, improved glycaemic control in db/db mice, and pancreatic islet and β-cell mass increased significantly following treatment with ZP3022 compared with vehicle.
No takes yet. Share an insight, caveat, or question.
Fosgerau et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: